首页> 外国专利> METHOD OF INHIBITING THE PROLIFERATION OF T AND/OR B LYMPHOCYTES VIA DIMETHYLARGININE DERIVATIVES AND LYMPHOCYTES PROLIFERATION INHIBITOR

METHOD OF INHIBITING THE PROLIFERATION OF T AND/OR B LYMPHOCYTES VIA DIMETHYLARGININE DERIVATIVES AND LYMPHOCYTES PROLIFERATION INHIBITOR

机译:通过二甲基碱衍生物和淋巴细胞增殖抑制剂抑制T和/或B淋巴细胞增殖的方法

摘要

The present invention belongs to the technical field of immunotherapy. A method of using dimethylarginine derivatives to inhibit the proliferation of lymphocyte. ADMA, SDMA, and their derivative DMGV can inhibit T cells and/or B cells proliferation in vitro by inducing mitochondrial ROS. ADMA and SDMA can induce mitochondrial ROS generation by the action of alanine-glyoxylate aminotransferase 2 (AGXT2), which converts both ADMA and SDMA into dimethylguanidino valeric acid (DMGV) in the mitochondria. The dimethylarginine dimethylamino hydrolase (DDAH) inhibitor PD404182 also inhibits T cell proliferation by allowing more ADMA and SDMA to be converted to DMGV. As a clinical relevance, DMGV effectively treated arthritis in mice which was caused by activated T cells.
机译:本发明属于免疫疗法技术领域。一种使用二甲基碱衍生物来抑制淋巴细胞增殖的方法。 ADMA,SDMA及其衍生物DMGV可以通过诱导线粒体ROS在体外抑制T细胞和/或B细胞增殖。 ADMA和SDMA可以通过丙氨酸 - 乙醛酸氨基转移酶2(AGXT2)的作用来诱导线粒体ROS产生,其将ADMA和SDMA转化为线粒体中的二甲基胍甲醛(DMGV)。二甲基碱二甲基氨基水解酶(DDAH)抑制剂PD404182还通过允许将更多ADMA和SDMA转化为DMGV来抑制T细胞增殖。作为临床相关性,DMGV在由活性T细胞引起的小鼠中有效处理关节炎。

著录项

  • 公开/公告号US2021196660A1

    专利类型

  • 公开/公告日2021-07-01

    原文格式PDF

  • 申请/专利权人 GUANGZHOU MEDICAL UNIVERSITY;

    申请/专利号US202016992111

  • 发明设计人 JONGDAE LEE;FENGYUAN YANG;LIYA SHEN;

    申请日2020-08-13

  • 分类号A61K31/198;A61P35/04;

  • 国家 US

  • 入库时间 2022-08-24 19:43:09

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号